Can Aripiprazole Cause Significant ALT Elevation?
Aripiprazole can cause significant ALT elevation, but this is rare and typically occurs in the context of drug-induced hepatotoxicity rather than as a common metabolic side effect.
Evidence from FDA Drug Labeling
The FDA label for aripiprazole (Abilify) specifically lists "aspartate aminotransferase increased" as a clinically important sign observed in overdose cases, indicating the drug's potential to affect liver enzymes 1. Importantly, the label states that no dosage adjustment is required for patients with hepatic impairment (mild to severe, Child-Pugh score 5-15), suggesting that aripiprazole itself does not typically cause progressive liver dysfunction during therapeutic use 1.
Clinical Case Evidence
A documented case report describes aripiprazole-induced hepatitis in a 28-year-old female who developed jaundice, nausea, and vomiting after 21 days of treatment (initially 10 mg/day, increased to 20 mg/day on day 12) 2. Laboratory analysis revealed:
- Very high ALT levels
- Minor to moderately elevated AST, alkaline phosphatase, GGT, and bilirubin
- Complete resolution after discontinuation and switch to paliperidone 2
This represents true drug-induced liver injury (DILI), which is uncommon but clinically significant when it occurs.
Comparative Metabolic Profile
In contrast to other atypical antipsychotics, aripiprazole demonstrates a favorable hepatic safety profile:
Short-term studies (5 days) showed that all hepatic enzymes were altered during aripiprazole treatment, but these changes were generally benign and part of normal metabolic adaptation 3
Switching studies demonstrated that patients switched from olanzapine to aripiprazole experienced significant decreases in ALT levels, suggesting aripiprazole may actually improve hepatic enzyme elevations caused by other antipsychotics 4, 5
Long-term efficacy studies (up to 52 weeks) characterize aripiprazole as having a "favorable adverse-effect profile" with low risk for metabolic complications 6
Clinical Interpretation Framework
When evaluating ALT elevations in patients on aripiprazole, apply the following approach based on gastroenterology guidelines 7:
For mild ALT elevations (<5× ULN):
- Consider alternative etiologies first (viral hepatitis, alcohol, other medications, fatty liver disease)
- Perform serologic testing for common hepatic diseases
- Monitor with serial liver chemistry tests 7
For significant elevations (≥5× ULN) or symptomatic patients:
- Discontinue aripiprazole immediately
- Evaluate for drug-induced liver injury using DILI criteria 8
- Consider more expeditious diagnostic workup including imaging and potentially liver biopsy 7
Key Clinical Caveats
- The prevalence of abnormal liver function tests with antipsychotic use is 32%, but clinically significant effects occur in only 4% of cases 2
- Aripiprazole-induced hepatotoxicity appears to be idiosyncratic rather than dose-dependent, as the documented case occurred at standard therapeutic doses 2
- Unlike olanzapine, aripiprazole does not appear to cause hepatic enzyme elevations through metabolic pathways related to weight gain or hyperglycemia 5
- Baseline liver function monitoring is prudent, but routine monitoring in asymptomatic patients is not mandated by the FDA label 1
In summary, while aripiprazole can rarely cause significant ALT elevation through idiosyncratic hepatotoxicity, it is generally considered one of the safer atypical antipsychotics for hepatic function and may even improve liver enzymes when substituted for more metabolically problematic agents.